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Phase I and Pharmacologic Study of Oral ZD9331 , A Novel
Nonpolyg lutamated Thymidylate Synthase Inhibi tor , in
Adul t Pat ients With Sol id Tumors
By Maja J.A. de Jonge, Cornelis J.A. Punt, Alex Sparreboom, Andre´ S.T. Planting, M.E.W.J. Peters,
Jacqueline van de Schraaf, Ann Jackman, Rob Smith, Pieter H.M. de Mulder, and Jaap Verweij
Purpose: To assess the toxicity profile and dose-
limiting toxicities (DLTs), to determine the maximum-
tolerated dose, and to study the pharmacokinetics of
ZD9331 when administered orally to patients with ad-
vanced solid tumors.
Patients and Methods: Patients were treated with
oral ZD9331 given once daily (od) or twice daily (bid)
for 5, 7, or 10 days; cycles were repeated every 21
days at doses ranging from 2.5 to 40 mg. For pharma-
cokinetic analysis, plasma sampling was performed
during the first course and assayed using a validated
liquid chromatographic–tandem mass spectrometry as-
say. Plasma levels of 2'-deoxyuridine were measured
as a surrogate marker for TS inhibition.
Results: Forty-two patients received a total of 166
courses. The DLTs were myelosuppression and skin
rash. Dose escalation of oral ZD9331 from 2.5 to 40
mg, as a single daily dose, resulted in a less than
proportional increase in the plasma area under the
concentration-time curve of ZD9331. The plasma drug
exposure per cycle for the schedules 20 mg od for 5
days, 10 mg od for 10 days, and 10 mg bid for 5 days,
all resulting in a total dose per cycle of 100 mg, were
comparable. One partial response was noted in a pa-
tient with gastric cancer.
Conclusion: DLTs in this phase I study of oral ZD9331
were myelosuppression and skin toxicity. The recom-
mended dose for phase II studies of oral ZD9331 is 20
mg od for 5 consecutive days, every 3 weeks.
J Clin Oncol 20:1923-1931. © 2002 by American
Society of Clinical Oncology.
ZD9331 ((S)-2-(2-FLUOR-4[N-(4-hydroxy-2,7-dimeth-ylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] ben-
zamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid) is a novel
water-soluble folate analog that potently and specifically
inhibits the enzyme thymidylate synthase (TS) (Fig 1). TS is
the rate-limiting enzyme in the biosynthesis of DNA cata-
lyzing the methylation of deoxyuridine monophosphate
(dUMP) to thymidine monophosphate, an essential precur-
sor for DNA synthesis.1 This reaction requires 5,10-meth-
ylene tetrahydrofolate as folate cofactor. Since thymidine
nucleotides are used exclusively for DNA synthesis, TS is
an important target for anticancer chemotherapy. Indeed,
several folate-based TS inhibitors have been developed and
have demonstrated clinical activity.2-4 However, resistance
to selective TS inhibitors might originate in a diminished
cellular uptake of the TS inhibitor by the reduced folate
carrier,5,6 impaired activation by folylpolyglutamate syn-
thetase (FPGS),5,7,8 and/or high folylpolyglutamyl hydro-
lase activity.5,9,10 To avoid the resistance caused by
alterations in FPGS expression or high folylpolyglutamyl
hydrolase activity, a common form of acquired and
probably intrinsic resistance to polyglutamated antifo-
lates, a nonpolyglutamatable TS inhibitor, ZD9331, was
developed.
ZD9331 is actively transported into cells by reduced
folate carrier proteins, which are thought to be expressed to
a greater extent by tumor cells than by normal cells, thus
potentially giving the drug a degree of tumor selectivity.11,12
In vitro studies have shown that ZD9331 is a potent
inhibitor of TS (Ki  0.4 ~ nmol/L),13 and antitumor
activity has been documented in vivo against human ovar-
ian, colon, non–small-cell lung, and gastric carcinoma
xenograft models.14 In addition, antitumor activity has been
observed after intravenous administration of ZD9331 in
patients with a variety of solid tumors.15-18 As expected in
view of the lack of intracellular drug retention of ZD9331,
the requirement for prolonged drug exposure to inhibit TS
and exert an antitumor effect suggested that ZD9331 might
be more active when given by a continuous infusion.
Alternatively, prolonged exposure might also be achieved in
a possibly more patient-convenient way, ie, oral adminis-
tration of the drug. When given orally to rodents, ZD9331
retained its antitumor activity (data on file, AstraZeneca,
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Alderley Park, United Kingdom). Toxicity observed in
animals after oral administration of ZD9331 included
weight loss, decreased food consumption, myelosuppres-
sion (especially leukocytopenia), and gastrointestinal toxic-
ity (data on file, AstraZeneca).
The pharmacokinetics of oral ZD9331 have been studied
in several animal species. Following oral administration of
ZD9331 to dogs, the absorption was rapid, with peak
plasma concentrations occurring after 0.25 to 2 hours. After
single and daily oral doses of 0.05, 0.1, and 0.2 mg/kg/d, the
area under the plasma concentration-time curve (AUC) of
ZD9331 increased proportionally with dose, and bioavail-
ability was approximately 80%. At higher dose levels (1
mg/kg/d), however, a less than dose-proportional increase in
both the maximal concentration and AUC of ZD9331 was
observed; a 25-fold increase in dose resulted in only a three-
to four-fold increase in plasma exposure, suggesting a
saturable absorption mechanism. Terminal half-life values
for ZD9331 after oral administration ranged from 7 to 11
hours in rats and from 5 to 70 hours in dogs. Excretion of
ZD9331 in both rat and dog was mainly via the bile as
unchanged parent compound. Biliary recirculation of
ZD9331 was apparent (data on file, AstraZeneca).
The objectives of this phase I study were to assess the
toxicity profile of oral ZD9331, to determine the maximum-
tolerated dose, to document any antitumor effects, and to
study the pharmacokinetics of ZD9331 administered orally
to patients with advanced solid tumors.
PATIENTS AND METHODS
Study Design
This was an open, nonrandomized, noncomparative, dose-escalating
trial of ZD9331 administered orally, once or twice daily, to adult
patients with refractory solid tumors. The trial was designed to comply
with the ethical principals of Good Clinical Practice in accordance with
the Declaration of Helsinki. The study was approved by the institu-
tions’ medical ethics committees, and all patients had to give written
informed consent before study entry.
Patient Selection
Patients with a histologically confirmed diagnosis of a malignant
solid tumor refractory to standard forms of therapy were eligible. Other
eligibility criteria included the following: age  18 years; World
Health Organization performance status  2; estimated life expectancy
more than 12 weeks; no previous anticancer therapy for at least 4 weeks
(6 weeks for nitrosoureas or mitomycin); and adequate hematopoietic
(absolute peripheral granulocyte count  2.0  109/L and platelet
count  100  109/L), hepatic (bilirubin  1.25 times upper limit of
normal [ULN] and serum AST and ALT  2.5 times ULN or  five
times ULN in case of liver metastases), and renal (serum creatinine 
1.25 times ULN) function. Concomitant administration of folic acid
was not allowed.
Treatment and Dose Escalation
ZD9331 was supplied as film-coated tablets that contained 0.5, 2, 5,
or 10 mg of the active drug, and these were stored at 4°C. The tablets
were taken once daily (od) or twice daily (bid) with a glass of water at
least 30 minutes before breakfast after an overnight fasting and, for bid
dosing, before the evening meal after at least 2 hours of fasting.
Patients were treated on an outpatient basis. The daily dose of ZD9331
was provided in separate pots, with each daily dosing clearly identifi-
able by the patient. Patients were instructed to record their daily amount
of tablets taken, the time of administration, and the timing in relation to
their meals. Compliance with the scheduled treatment was assessed at
the end of each course, by counting the used and returned tablets of
ZD9331 in relation to the record kept by the patient for the given cycle.
The starting dose of ZD9331, 2.5 mg given orally od for 5 days, was
one third of the minimal toxic dose in dogs. Courses were to be
repeated every 21 days. Dose escalations were based on the prior dose
level toxicity. If no toxicity (excluding alopecia, mild or moderate
fatigue, grade 1 or 2 nausea and vomiting, and transient rise in AST
and/or ALT) was observed at the previous dose level, a 100% dosage
increment was allowed. In this accelerated stage, at least one patient
was treated at each dose level. However, if toxicity was observed, a
dose escalation of 15% to 67% (determined by the worst significant
toxicity) according to a modified Fibonacci scheme was prescribed.
From that time onward, at least three patients were entered at each dose
level. Once the dose-limiting toxicity (DLT) was observed in one out of
three patients, three additional patients were treated at that dose level.
Based on pharmacokinetic findings, the dosing scheme and the duration of
drug administration could be amended during the study. The maximum-
tolerated dose was defined as one dose level below the dose that induced
DLTs in more than 50% of patients during course 1. DLTs were defined
according to the National Cancer Institute’s common toxicity criteria
(version December 1994) and comprised grade 4 neutropenia for at least 7
days, grade 4 neutropenic fever, grade 4 thrombocytopenia, and nonhe-
matologic toxicity  grade 3 not ameliorated by symptomatic measures
(excluding a transient rise in AST and/or ALT). Intrapatient dose escala-
tion was only allowed during the accelerated phase of dose escalation. If a
patient encountered DLT, the dose of ZD9331 was decreased by one dose
level at retreatment. The treatment was resumed when the neutrophil count
had recovered to 2.0  109/L, the platelet count to 100  109/L, and
all other redosing criteria were met.
Treatment Assessment
Before therapy, a complete medical history was taken and a physical
examination was performed. A complete blood cell count including WBC
differential and serum biochemistry, which involved sodium, potassium,
calcium, phosphorus, urea, creatinine, total protein, albumin, total biliru-
bin, alkaline phosphatase, AST, ALT, gamma-glutamyl transferase, glu-
cose, and uric acid, were performed, as were urinalysis, ECG, and a chest
x-ray. Weekly evaluations included history, physical examination, toxicity
assessment according to the common toxicity criteria, and serum chemis-
try. The complete blood cell count was determined twice weekly. Tumor
Fig 1. Chemical structure of ZD9331.
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evaluation was performed after every two courses according to the World
Health Organization criteria for response. Patients were taken off protocol
at the onset of disease progression.
Sample Collection and Drug Analysis
For pharmacokinetic analysis, 23 to 29 blood samples (~ 3 mL) were
obtained from an indwelling intravenous cannula and collected in vials
containing lithium heparin as anticoagulant. The samples were taken
before dosing, at 1, 2, 4, 6, 8, 12, and 24 hours after dosing on days 1
and 4, at 2 hours after dosing on day 2, before dosing on day 3, and 2
hours after dosing on day 3 of the first course. Additional samples were
taken 72, 168, 240, and 408 hours after the last dosing on day 5. All
samples were centrifuged immediately after sampling for 10 minutes at
1,000  g, and the plasma supernatant was snap-frozen at 20°C and
remained frozen until analysis.
The protocol allowed changes in the administration scheme of
ZD9331 based on pharmacokinetic data obtained during the study.
Indeed, several other schemes were studied. This resulted in an
adaptation of the pharmacokinetic sampling points.
In the 5-day bid regimen, blood samples were taken before the morning
and evening doses of the drug, 1, 2, 4, 6, and 8 hours after the morning
dose, and 1, 2, and 4 hours after the evening dose on days 1 and 4 (or 5)
of the first cycle. Additional samples were taken before the morning and
evening doses on days 2 and 3. During the 7-day od regimen, samples for
pharmacokinetic analysis were taken on days 1 and 7 before dosing, at 1,
2, 4, 6, and 12 hours after dosing, and before dosing and 2 hours after
dosing on days 2, 3, and 6. For the 10-day od regimen, samples were taken
before dosing, at 1, 2, 4, 6, 12, and 24 hours after dosing on days 1 and 10,
before dosing and 2 hours after dosing on days 2, 3, 4, 7, 8, and 9, and 120,
192, and 288 hours after the last dosing on day 10. Additional samples
were taken up to 288, 360, and 480 hours after the final dosing for the 10-,
7-, and 5-day regimens, respectively. Concentrations of ZD9331 were
determined according to a validated liquid chromatographic–tandem mass
spectrometry assay.
Inhibition of TS leads to a rise in the level of intracellular dUMP,
which is phosphorylated to 2'deoxyuridine (dUrd). dUrd is effluxed
from cells, leading to a rise in plasma dUrd.19,20 Thus, plasma dUrd can
be used as a surrogate marker for TS inhibition.21,22 Samples (nos. 7 to
11) for the determination of plasma dUrd (~ 8 mL) were taken from
dose level 10 mg bid for 5 days onward and collected in vials
containing lithium heparin as anticoagulant. The samples were obtained
before dosing on days 1 to 5, on days 8, 15, and 22 in the 5-day
regimens, on days 1 to 3, 6 to 8, 10, 14, 17, and 22 in the 7-day
regimen, and on days 1 to 4, 7 to 11, 15, 18, and 22 in the 10-day
regimen. All samples were centrifuged immediately at 1,000  g for 10
minutes at 4°C, and the plasma supernatant was snap-frozen at 20°C
until high-performance liquid chromatographic analysis. Concentra-
tions of plasma dUrd were determined according to a validated
high-performance liquid chromatographic assay, which was performed
as described previously,21 with fluorescence detection at 301 nm.
Pharmacokinetic and Pharmacodynamic Data Analysis
The terminal disposition half-life of ZD9331 was calculated as ln2/k,
where k is the terminal elimination rate constant (expressed in hours1)
following the last dose. The peak plasma concentrations and the time to
peak plasma concentration were determined graphically from the (ob-
served) experimental values. The AUC of ZD9331 was estimated using the
experimental values (trapezoidal rule) with extrapolation to infinity using
the terminal elimination rate constant, defined as the slope of at least the
final three data points of the log-linear concentration-time plot.
Pharmacokinetic/pharmacodynamic relationships between ZD9331
kinetic parameters and hematologic toxicity associated with drug
administration were evaluated using the Siphar software package
(InnaPhase, Philadelphia, PA). Only the first course of each patient was
taken into consideration to avoid potentially confounding bias due to
cumulative toxicity. All data were fitted to a sigmoidal maximum effect
model based on the modified Hill equation, as follows:
E E0  Emax KP/KP  KP50.
In this equation, E0 is the minimum reduction possible, Emax is the
maximum response, fixed at 100 (continuous variables) or 4 (discrete
variable), KP is the pharmacokinetic parameter of interest, KP50 is the
value of the pharmacokinetic parameter predicted to result in half of the
maximum response, and gamma () is the Hill constant describing the
sigmoidicity of the curve.
Statistical Analysis
All pharmacokinetic parameters are reported as mean values  SD.
The pharmacokinetic-pharmacodynamic models were evaluated for
goodness of fit by minimization of sums of the squared residuals and by
reduction of the estimated coefficient of variation for fitted parameters.
Significance of these relationships was assessed by construction of
contingency tables with subsequent 2 analysis. The correlations
between the individual AUC values and the administered dose level
was analyzed by means of Spearman’s correlation coefficient (rho) and
a linear regression analysis. Variability in pharmacokinetic parameters
between the various dose levels was evaluated by the Kruskal-Wallis
statistic followed by Dunn’s multiple comparison test. Interpatient
variability in oral clearance of ZD9331 was correlated with patient
characteristics, including body-surface area, sex, and age, using uni-
Table 1. Patient Characteristics
Characteristic
No. of
Patients
No. entered 42
No. assessable 42
Age, years
Median 58
Range 23-74
Sex
Female 10
Male 32
WHO performance status
0 17
1 20
2 5
Tumor type
Colorectal 20
(A)CUP 4
Renal 3
(N)SCLC 3
Miscellaneous 12
Previous treatment
Chemotherapy 20
Chemotherapy and radiation 15
None 7
Abbreviations: (A)CUP, (adeno)carcinoma of unknown primary; (N)SCLC,
(non)small-cell lung cancer; WHO, World Health Organization.
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variate linear regression analysis. A similar analysis was performed to
evaluate potential relationships between the total cumulative exposure
(AUC0-504) to ZD9331 and measures of renal function (serum creati-
nine values) and hepatic function (bilirubin, AST, ALT, and alkaline
phosphatase). Probability values and adjusted r2 values were calculated
as a measurement for correlation. Statistical calculations were per-
formed using the Number Cruncher Statistical System version 5.X (J.L.
Hintze, East Kaysville, UT, 1992). Probability values of less than .05
were regarded as statistically significant.
RESULTS
A total of 42 patients were enrolled onto the study at two
institutions. Patient characteristics are listed in Table 1.
Thirty-nine patients were eligible. Three patients were
ineligible based on marginally elevated serum bilirubin
levels; however, all patients were taken into consideration
for the assessment of toxicity and response. The majority of
the patients were either asymptomatic or had only mild
symptoms. The most common tumor type was colorectal
cancer. The total number of assessable courses was 166, and
the median number of courses per patient was two (range,
one to 14). Dose levels studied were 2.5, 5, 10, 20, 30, and
40 mg od for 5 days, 10 mg bid for 5 days, 10 mg od for 10
days, and 20 mg od for 7 days (Table 2). All cycles were
repeated once every 3 weeks. In one patient treated at 10 mg
od for 5 days, the dose of ZD9331 was escalated from the
third cycle onward to 20 mg for 5 days, as allowed by
protocol. In two patients (20 mg/d, 40 mg/d) dose reduc-
tions were necessary because of toxicity. Treatment was
discontinued in five patients because of side effects (hema-
tologic toxicity in one patient, skin toxicity in three, and
skin/hematologic toxicity in one).
Tolerability
At first, the dose of ZD9331 administered daily was
escalated. At the dose level 10 mg od for 5 days, one patient
experienced grade 3 hyperbilirubinemia. In view of the fact
that the patient concomitantly suffered from pneumonia and
cardiac dysfunction, it was decided to consider the hyper-
bilirubinemia to be not drug-related. Dose escalation pro-
ceeded. At 40 mg od for 5 days, DLT was first encountered
and consisted of grade 4 neutro- and thrombocytopenia in
one out of 6 patients. However, pharmacokinetic data, to be
described in more detail below, revealed no increase in
plasma exposure to ZD9331 with doses over 20 mg. In view
of these findings, no further dose escalation was pursued
and the following alternative regimens were studied: 10 mg
bid dosed for 5 days, 20 mg od for 7 days, and prolonged
administration of 10 mg od for 10 days. At the 10-mg bid
dose level, two out of six patients experienced DLT con-
sisting of a grade 3 rash; in one of the two patients, it was
in conjunction with grade 4 neutro- and thrombocytopenia.
Also, at the dose level of 20 mg od for 7 days, three out of
five patients developed a grade 3 rash, and in the regimen
applying the 10-day dosing of 10 mg, one patient out of six
developed a grade 3 rash and another patient had grade 4
thrombocytopenia. At this point it was decided to extend the
cohort of patients treated with 20 mg od for 5 days to 12
Fig 2. Typical example of grade 3 rash.
Table 2. Dose Levels and Number of Patients Entered
Dose (mg/d) Days per Cycle
Total Dose per Cycle
(mg) No. of Patients
2.5 od 5 12.5 2
5 od 5 25 1
10 od 5 50 1
20 od 5 100 12 (1)*
30 od 5 150 3 (1)*
40 od 5 200 6
10 bid 5 100 6 (1)*
10 od 10 100 6
20 od 7 140 5
*Number in parentheses indicates patient treated at this dose level after dose
escalation or reduction.
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patients. One of the additional patients developed a grade 3
rash in conjunction with grade 3 diarrhea during the first
treatment course, but no further DLTs were noted. In view
of these data and the pharmacokinetic data, 20 mg od for 5
days was considered the recommended dose for further
study of this regimen.
Skin toxicity was the predominant nonhematologic tox-
icity observed over the total dose range studied and was
encountered in 29% of the cycles and consisted of a rash
predominantly located on the trunk and extremities (Fig 2).
Microscopical examination of a skin biopsy revealed an
infiltration with lymphocytes and eosinophils compatible
with a toxic dermatitis. The median day of onset of the skin
reaction was day 7 after the start of the treatment (range,
days 1 to 17), with a median duration of 12 days (range, 1
to 44 days). There were no indications for cumulative
toxicity. Dose reduction did not result in diminished skin
toxicity. Treatment with antihistamines and corticosteroids
only minimally alleviated the symptoms. One patient, who
experienced a grade 3 rash in the first course, received
subsequent cycles of treatment with dexamethasone 3 mg
bid from the day before the start of therapy until the day
after the last ZD9331 administration in each cycle. In this
patient rash was prevented in all further 13 cycles.
Another frequently observed nonhematologic side effect
was fever in absence of infection. It was documented in
21% of the cycles and in 17 out of 42 patients, with a
median day of onset of day 5 (range, days 2 to 20) and a
median duration of 2 days.
Other types of nonhematologic side effects (nausea,
vomiting, mucositis, myalgia/arthralgia, and alopecia) were
not severe (Table 3). No grade 3 or 4 nausea or vomiting
was observed. Grade 1 or 2 nausea and vomiting occurred in
32% of the cycles but did not have any implications for drug
administration. Nine patients experienced grade 1 alopecia
and one patient experienced grade 2 alopecia. In 14% of the
cycles, in 12 out of 42 patients, a transient asymptomatic
rise in transaminases was observed at all doses with a
median day of onset of day 5. Four patients had grade 3 or
4 bilirubinemia in conjunction with elevated levels of liver
transaminases; in two of them, the toxicity was considered
to be drug related. The grade 3 or 4 bilirubinemia occurred
in all but one patient at doses  20 mg/d and during the
third or subsequent cycles. There was no association be-
tween dosage and regimen of ZD9331 and the incidence of
hepatic and renal abnormalities.
Hematologic toxicity was mild and mostly limited to
grade 1 or 2 neutropenia and thrombocytopenia. Grade 3
or 4 neutropenia and thrombocytopenia were only ob-
served in six patients (Table 3). No treatment-related
deaths were reported.
Responses
One partial response was observed, lasting 30 weeks, in a
patient with gastric cancer. Eighteen patients experienced
stabilization of their disease (10 patients with colorectal
carcinoma, two patients with non–small-cell lung cancer,
and one patient each with adenocarcinoma of unknown
primary, carcinoma of the stomach, carcinoma of the
bladder, pancreatic carcinoma, renal carcinoma, and carci-
noma of the cervix) for a median duration of 18 weeks
(range, 11 to 52	 weeks).
Pharmacokinetics and Pharmacodynamics
Full kinetic data were obtained from all 42 patients after
the administration of ZD9331. The plasma concentration-
time profiles of ZD9331 were similar for all patients
studied, with a representative profile shown in Fig 3.
ZD9331 pharmacokinetics were characterized by rapid
absorption after oral dosing, with peak plasma levels occur-
ring at approximately 1 to 2 hours after dosing. The mean
estimated pharmacokinetic data for ZD9331 are summa-
rized in Table 4 as a function of the dose. Dose escalation
of oral ZD9331 from 2.5 to 20 mg/d resulted in a linear
increase in AUC. Increasing the dose over 20 mg per
administration did not result in a further rise of the AUC. On
Table 3. Worst Toxicity per Patient per Dose Level
Dose (mg)  Days
Neutropenia Thrombocytopenia Transaminases Skin Diarrhea
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
2.5 od  5     1     
5 od  5          
10 od  5          
20 od  5     3  1  1 
30 od  5   1       
40 od  5    1 2  1   
10 bid  5 1 1 1 1 2  2   1
10 od  10    1   1   
20 od  7   1  2  3   
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the basis of this observation, alternative regimens were
studied with prolonged administration of ZD9331 or mul-
tiple dosing per day. The plasma drug exposures per cycle
(AUC0-504) for the 20-mg od 5-day regimen, 10-mg od
10-day regimen, and 10-mg bid 5-day regimen, all of which
resulted in a total dose per cycle of 100 mg, were compa-
rable. In addition, similar exposure was observed for the
20-mg od 7-day regimen (Table 4).
Substantial interpatient kinetic variability was apparent,
with coefficients of variation in AUC values up to 50%. In
one patient, treated with dexamethasone to prevent skin
toxicity, additional pharmacokinetic sampling was per-
formed in the fourth cycle. The AUC of ZD9331 showed an
increase of approximately 40% compared with cycle 1 (data
not shown). It is not possible to conclude whether these data
represent a real increase or are a reflection of the intrapatient
variability in pharmacokinetics. However, the maximal
concentration and serum half-life of ZD9331 was compara-
ble between the two cycles. Elimination of ZD9331 from
the central plasma compartment was characterized by decay
in an apparent biexponential manner, based on conventional
compartmental modeling using weighted least-squares anal-
ysis with a weighting factor of 1/Y. The estimated elimina-
tion half-life was relatively constant in all subjects (ie, 3.5
days) and was not dependent on the dose of ZD9331. The
long half-life resulted in accumulation of ZD9331, such that
exposure was two-fold higher by the last day of dosing (data
not shown).
The apparent oral clearance of ZD9331 based on the first
24-hour sampling time period was independent of the
administered dose (P  .080). Similarly, the AUC0-24 was
linearly related to the administered ZD9331 dose (Spear-
man’s rho  0.53). The apparent volume of distribution
ranged from 62.3 to 256.5 L, which suggests significant
distribution of ZD9331 into the extravascular tissues. Using
linear regression analysis, we found that ZD9331 oral
clearance was not significantly related to patient body-
surface area (P  .56; r2  .0087), consistent with previous
observations.16 In a univariate regression analysis, oral
clearance was also not related to patient age (P  .914;
r 2  .0003), and no differences were observed between
male and female patients (P  .085, two-tailed unpaired
Student’s t test). In an attempt to correlate variability in
oral clearance of ZD9331 with renal and hepatic function
of individual patients, several additional analyses were
conducted using clearance as the independent variable.
These revealed that AUC0-504 in the entire population
was strongly related to serum creatinine (P  .0001;
r20.45) and also, albeit weakly, to baseline bilirubin
levels (P  .038; r2  .10) but not to AST (P  .11; r2
 .062), ALT (P  .15; r 2  .052), or alkaline
phosphatase (P  .97; r2  .00001).
Fig 3. Geometric mean plasma concentration-time profile of ZD9331
measured in the first treatment course after oral administration of ZD9331 at
a dose level of 20 mg in a daily-times-five schedule (n  12).
Table 4. Summary of Pharmacokinetics of Oral ZD9331
Dose (mg)  Days
Total Dose per Cycle
(mg)
No. of
Patients Cmax (ng/mL)
AUC0-24hours
(g  h/mL)
AUC0-

(g  h/mL) CL/f (L/h) t1/2 (hours)
2.5 od  5 12.5 2 183  32 1.79  0.40 17.8  0.70 1.17  1.67 61.9  28.9
5 od  5 25 1 156 1.88 30.2 2.66 155
10 od  5 50 1 614 7.61 103 1.31 104
20 od  5 100 12 686  238 8.22  3.40 75.9  34.7 2.71  2.57 86.4  40.3
30 od  5 150 3 846  208 12.3  2.74 101  13.2 2.49  0.581 93.4  57.3
40 od  5 200 6 897  265 10.9  4.45 108  38.6 4.08  1.82 96.0  29.8
10 bid  5 100 6 797  192 10.9  1.84 108  31.0 1.86  0.332 93.4  43.7
10 od  10 100 6 485  103 5.24  1.65 124  33.3 2.01  0.634 53.6  20.2
20 od  7 140 5 721  234 8.21  1.84 135  25.0 2.53  0.819 81.9  16.9
NOTE. Kinetic values are mean values  SD.
Abbreviations: Cmax, peak plasma level; AUC, area under the plasma concentration-time curve; CL/f, apparent total body clearance; t1/2, terminal elimination
half-life.
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Correlations were also attempted between pharmacoki-
netic values based on AUC0-504 values and the experienced
hematologic and skin toxicity attained after the first cycle.
Hematologic pharmacodynamic analysis revealed no signif-
icant relationship between the percentage decrease in WBC
(P  .10), although AUC0-504 was related to both the
percentage decrease in absolute neutrophil count (P 
.0004; r2  .55) and platelet count (P  .0001; r2  .63)
using a sigmoidal maximum-effect model (Fig 4). For skin
toxicity, although the patients with the highest exposure
were linked to grade 3 or 4 toxicity, there did not seem to be
a direct relationship between AUC values and toxicity. A
similar relationship could be established between the abso-
lute dose of ZD9331 administered and the percentage
decrease in absolute neutrophil count (P  .008; r2  .401)
and platelet count (P  .031; r2  .329). In those patients
from whom blood samples were collected for analysis of
plasma dUrd, increased levels of plasma dUrd were dem-
onstrated in all but one patient. Figure 5 depicts the
elevation of plasma dUrd for patients in the 20-mg od 5-day
regimen. The maximum rise in plasma dUrd, usually 200%
to 400% of the pretreatment value, was generally observed
on day 2. No correlation between dUrd rise and dose or
regimen could be discerned, and in most patients, dUrd
levels returned to pretreatment values from 3 days after
dosing onward.
DISCUSSION
The development of orally administered anticancer
agents provides a convenient method of prolonged drug
administration and the opportunity for cost-effective outpa-
tient therapy. Moreover, patients have a clear preference for
oral chemotherapy when equally effective as intravenous
administration.23 Several TS inhibitors, such as capecitabine
and uracil plus tegafur, have shown promising results by
oral administration.24,25 ZD9331 is a novel TS inhibitor that
does not need to be activated by FPGS, thereby circumvent-
ing a common form of resistance of the tumor cell to TS
inhibition. This, however, also results in a limited intracel-
lular retention time of ZD9331 and might result in the
requirement for prolonged dosing schedules in order to
optimize drug exposure to inhibit TS and achievement of
antitumor efficacy. When prolonged exposure is desirable,
oral administration is certainly the most appealing route of
administration. The aim of this phase I study was to assess
the toxicity profile of oral ZD9331, to determine the
Fig 4. Relationships between AUC0-504 of ZD9331 and hematologic
pharmacodynamics, expressed as percentage decrease in absolute neutro-
phil count (A) and platelet count (B). The open symbols represent data from
patients treated at the 20-mg dose level in a daily-times-five schedule.
Fig 5. Mean percentage increase in plasma dUrd compared with pre-
treatment values during cycle 1 in five patients, after oral administration of
ZD9331 at 20 mg od for 5 days.
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recommended dose for further study, to assess antitumor
efficacy, and to study the pharmacokinetics of the drug.
The DLTs of oral ZD9331 in our study consisted of a
combination of skin toxicity and myelosuppression. The
skin toxicity observed was a rash, predominantly located on
the trunk and extremities. This is in contrast to the hand-foot
syndrome, the skin toxicity most often observed during
treatment with other TS inhibitors. Furthermore, after the
intravenous administration of ZD9331, skin toxicity was
also observed, albeit less frequently.15,16,26 This difference
in frequency of occurrence was not attributed to an altered
metabolism of ZD9331 after oral administration, as a recent
14C clinical study has shown that the parent compound is
responsible for the majority of circulating activity.27 The
median day of onset of the skin rash was day 7, independent
of the dosing regimen studied. If a patient experienced skin
toxicity in the first cycle, this was predictive for skin
toxicity in following cycles. The reappearance of the rash in
the following cycles was prevented by pretreatment with
dexamethasone. Since at the recommended dose level grade
3 rash only was seen in one patient, prophylactic treatment
with corticosteroids for all patients is not recommended.
In 12 out of 42 patients (14% of the cycles), a transient
asymptomatic rise in liver transaminases could be observed.
This phenomenon is also known from therapy with ralti-
trexed, during which treatment 13% of the patients will
develop a transient rise in transaminases.28 After the intra-
venous administration of ZD9331, elevated transaminases
were observed in 17 of 59 patients.16 Other nonhematologic
and hematologic side effects were mild. In trials studying
the intravenous administration of ZD9331, the DLT con-
sisted of a combination of neutro- and thrombocytopenia.
In view of the observed toxicity and the pharmacokinetic
data in the present study, indicating that optimal exposure
to ZD9331 was achieved with the regimens administering
100 mg of ZD9331 per cycle, 20 mg od for 5 days,
repeated every 3 weeks, is recommended for further
studies of this regimen.
In the present study, the pharmacokinetics of ZD9331
were linear in the dose range 2.5 to 20 mg od. However, at
higher doses, a nonlinear increase in AUC was observed.
This phenomenon has also been described after the intrave-
nous administration of the drug, albeit to a lesser extent.16,26
Also, multiple daily dosing or extension of the treatment
time did not result in an increase in exposure to the drug per
cycle. The exposure to ZD9331 per cycle was comparable
among the three regimens administering 100 mg per cycle,
ie, 20 mg od for 5 days, 10 mg bid for 5 days, and 10 mg
od for 10 days. Dose-dependent nonlinearity can be caused
by a number of mechanisms. Since the drug is administered
orally, absorption might become saturated above a certain
dose administered. In that case, however, one would have
expected that multiple daily dosing would have improved
the exposure to the drug. Oral bioavailability studies of
ZD9331 are currently ongoing. A dose-dependent nonlin-
earity in drug exposure could also be the result of the
saturation of reabsorption processes. Excretion of ZD9331
in both the rat and dog was mainly via the bile. In the rat,
biliary recirculation of ZD9331 could encompass a satu-
rable active transport system. Enterohepatic circulation
of ZD9331 in man has not yet been demonstrated.
Saturation of renal tubular reabsorption or nonlinear
protein binding may also account for a change in clear-
ance with increasing dose.
ZD9331 was administered at fixed doses during the
study. Using linear regression analysis, ZD9331 oral clear-
ance was not significantly related to patient body-surface
area, which confirms that the application of dosing per
body-surface area would not have optimized dosing.
Inhibition of TS leads to a rise in the level of intracellular
dUMP, which is phosphorylated to dUrd. dUrd is effluxed
from cells, leading to a rise in plasma dUrd.20,21 Thus,
plasma dUrd can be used as a surrogate marker for TS
inhibition.19,22 The limited sampling for the determination
of plasma dUrd undertaken during this study confirmed that
plasma levels of dUrd increased above pretreatment values
for the duration of the drug administration, thereby suggest-
ing that plasma exposure to ZD9331 was sufficient to
induce TS inhibition.
In view of the long half-life of ZD9331 and the indication
of the existence of TS inhibition even 3 days after drug
administration, alternative schedules of drug dosing might
provide a better balance between toxicity and efficacy.
The current study has shown that oral ZD9331 has
some antitumor activity in a range of tumor types. One
partial response was observed in a patient with metastatic
gastric cancer, and in another 18 patients, disease stabi-
lization was achieved.
REFERENCES
1. Carreras CW, Santi DV: The catalytic mechanism and structure
of thymidylate synthase. Annu Rev Biochem 64:721-762, 1995
2. Jackman AL, Calvert AH: Folate-based thymidylate synthase
inhibitors as anticancer agents. Ann Oncol 6:871-881, 1995
3. Touroutoglou N, Pazdur R: Thymidylate synthase inhibitors. Clin
Cancer Res 2:227-243, 1996
4. Takimoto CH: Antifolates in clinical development. Semin Oncol
24:S18-40-S18-51, 1997 (suppl 18)
1930 DE JONGE ET AL
from 131.174.248.154
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on September 15, 2016
Copyright © 2002 American Society of Clinical Oncology. All rights reserved.
5. Jackman AL, Kelland LR, Kimbell R, et al: Mechanisms of
acquired resistance to the quinazoline thymidylate synthase inhibitor
ZD1694 (Tomudex) in one mouse and three human cell lines. Br J
Cancer 71:914-924, 1995
6. Takemura Y, Gibson W, Kimbell R, et al: Cellular pharmacoki-
netics of ZD1694 in cultured human leukemia cells sensitive, or made
resistant, to this drug. J Cancer Res Clin Oncol 122:109-117, 1996
7. Jackman AL, Kimbell R, Brown M, et al: The antitumour activity
of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase
inhibitor. Adv Exp Med Biol 370:185-188, 1994
8. Takemura Y, Kobayashi H, Gibson W, et al: The influence of
drug-exposure conditions on the development of resistance to metho-
trexate or ZD1694 in cultured human leukemia cells. Int J Cancer
66:29-36, 1996
9. Kobayashi H, Takemura Y, Miyachi H: Molecular characteriza-
tion of human acute leukemia cell line resistant to ZD9331, a
non-polyglutamatable thymidylate synthase inhibitor. Cancer Che-
mother Pharmacol 42:105-110, 1998
10. Freemantle SJ, Jackman AL, Kelland LR, et al: Molecular
characterisation of two cell lines selected for resistance to the folate-
based thymidylate synthase inhibitor, ZD1694. Br J Cancer 71:925-
930, 1995
11. Sirotnak FM, DeGraw JI, Moccio DM, et al: New folate
analogues of the 10-deaza-aminopterin series: Basis for structural
design and biochemical and pharmacologic properties. Cancer Che-
mother Pharmacol 12:18-25, 1984
12. Sirotnak FM: Obligate genetic expression in tumor cells of a
fetal membrane property mediating “folate” transport: Biological
significance and implications for improved therapy of human cancer.
Cancer Res 45:3992-4000, 1985
13. Jackman AL, Kimbell R, Aherne GW, et al: Cellular pharma-
cology and in vivo activity of a new anticancer agent, ZD9331: A
water-soluble, non-polyglutamatable, quinazoline-based inhibitor of
thymidylate synthase. Clin Cancer Res 3:911-921, 1997
14. Stephens TC, Smith MN, McCloskey ML: ZD9331, a novel
non-polyglutamated thymidylate synthase inhibitor: In vivo antitumour
efficacy and toxicity to normal murine tissues. Proc Am Assoc Cancer
Res 35:305, 1994 (abstr)
15. Diab S, Britten C, Smith R, et al: A phase I pharmacokinetic
study of ZD9331, a novel long-acting thymidylate synthase inhibitor on
a single dosing every 3 weeks schedule. 10th NCI-EORTC Symp New
Drugs Cancer Ther 1998, p 160 (abstr 611)
16. Goh BC, Ratain MJ, Bertucci D, et al: Phase I study of ZD9331
on short daily intravenous bolus infusion for 5 days every 3 weeks with
fixed dosing recommendations. J Clin Oncol 19:1476-1484, 2001
17. Plummer R, Rees C, Judson I, et al: Phase I trial of ZD9331 in
adult patients with refractory solid malignancies administered by
30-minute infusion on days 1 and 8 with the cycle repeated every 3
weeks. Eur J Cancer 35:S285, 1999 (suppl 4, abstr 1143)
18. Trigo J, Rees C, Beale P, et al: Phase I trial of ZD9331, a
non-polyglutamatable thymidylate synthase inhibitor given as a 5-day
continuous infusion every 3 weeks. Eur J Cancer 35:S286, 1999 (suppl
4, abstr 1149)
19. Aherne W, Hardcastle A, Kelland L, et al: The measurement of
deoxynucleotide (dNTP) pools by radioimmunoassay (RIA). Adv Exp
Med Biol 370:801-804, 1994
20. Aherne W, Hardcastle A, Brown S, et al: The effect of ZD9331,
a non-polyglutamated quinazoline thymidylate synthase inhibitor, on
TTP and dUMP pools. Br J Cancer 71:67, 1995 (suppl 24, abstr 171)
21. Mitchell F, Lynn S, Jackman AL: Modified high-performance
liquid chromatography assay for the measurement of 2'-deoxyuridine in
human plasma and its application to pharmacodynamic studies of
antimetabolite drugs. J Chromatogr B Biomed Sci Appl 744:351-358,
2000
22. Jackman AL, Mitchell F, Lynn S, et al: Plasma 2'deoxyuridine
(dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in
patients treated with ZD9331. Proc Am Soc Clin Oncol 18:171a, 1999
(abstr 654)
23. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral
versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115,
1997
24. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies
of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol
16:1795-1802, 1998
25. Hoff PM: The tegafur-based dihydropyrimidine dehydrogenase
inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: A
review of their clinical development and therapeutic potential. Invest
New Drugs 18:331-342, 2000
26. Rees C, Beale P, Trigo J, et al: Phase I trial of ZD9331, a
non-polyglutamatable thymidylate synthase (TS) inhibitor given as a
5-day continuous infusion. Proc Am Soc Clin Oncol 18:171a, 1999
(abstr 657)
27. Scurr M, Judson I, O’Donnell A, et al: ZD9331: A phase I trial
to assess the metabolism, excretion and pharmacokinetics of single-
dose 260 mg/m2 [14C]-ZD9331 infused over 30 minutes in patients
with advanced solid tumours. Proc Am Soc Clin Oncol 20:88a, 2001
(abstr 350)
28. Cocconi G, Cunningham D, Van Cutsem E, et al: Open,
randomized, multicenter trial of raltitrexed versus fluorouracil plus
high-dose leucovorin in patients with advanced colorectal cancer.
J Clin Oncol 16:2943-2952, 1998
1931ORAL ZD9331 IN ADULTS WITH SOLID TUMORS
from 131.174.248.154
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on September 15, 2016
Copyright © 2002 American Society of Clinical Oncology. All rights reserved.
